Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 9/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.44 |
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | PI4KA | P42356 | 1/20 | 0.44 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.44 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.44 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL838829 | 0.88 | P2RX7 (0.46) | GCKALDH1A1MAPTMAPK1KDM4E | |
| SCHEMBL839270 | 0.86 | GCK (0.46) | GCKALDH1A1MAPTSMN1; SMN2MAPK1 | |
| SCHEMBL839442 | 0.85 | TP53 (0.46) | GCKALDH1A1MAPTSMN1; SMN2MAPK1 | |
| SCHEMBL878705 | 0.85 | GCK (0.47) | GCKALDH1A1MAPTSMN1; SMN2MAPK1 | |
| SCHEMBL12000946 | 0.85 | SLC2A1 (0.53) | ALDH1A1MAPTSMN1; SMN2KDM4EMEN1 | |
| SCHEMBL839657 | 0.85 | SLC2A1 (0.54) | ALDH1A1MAPTSMN1; SMN2KDM4EMEN1 | |
| SCHEMBL6253182 | 0.85 | MAPT (0.47) | ALDH1A1MAPTMAPK1KDM4EMEN1 | |
| SCHEMBL839952 | 0.83 | MAPK14 (0.47) | GCKALDH1A1MAPTSMN1; SMN2KDM4E | |
| SCHEMBL25975269 | 0.82 | MAPT (0.53) | GCKALDH1A1MAPTSMN1; SMN2MAPK1 | |
| SCHEMBL839353 | 0.82 | TP53 (0.48) | ALDH1A1MAPTSMN1; SMN2KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143263-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2012-03-27 | — | — | US | disclosed |
| US-8143263-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2012-03-27 | — | — | US | disclosed |
| US-8143263-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2012-03-27 | — | — | US | disclosed |
| EP-2324028-A2 | THERAPEUTIC AGENTS 414 | AstraZeneca AB (SE) | 2011-05-25 | — | — | EP | disclosed |
| US-20100093757-A1 | THERAPEUTIC AGENTS 414 | ASTRAZENECA AB (SE) | 2010-04-15 | — | — | US | disclosed |
| US-20100093757-A1 | THERAPEUTIC AGENTS 414 | ASTRAZENECA AB (SE) | 2010-04-15 | — | — | US | disclosed |
| US-20100093757-A1 | THERAPEUTIC AGENTS 414 | ASTRAZENECA AB (SE) | 2010-04-15 | — | — | US | disclosed |
| WO-2010015849-A2 | THERAPEUTIC AGENTS 414 | ASTRAZENECA AB (SE) | 2010-02-11 | — | — | WO | disclosed |
| WO-2010015849-A2 | THERAPEUTIC AGENTS 414 | ASTRAZENECA AB (SE) | 2010-02-11 | — | — | WO | disclosed |
| US-20070197559-A1 | Aryl substituted purine analogues | NEUROGEN CORPORATION | 2007-08-23 | — | — | US | disclosed |
| US-20070197559-A1 | Aryl substituted purine analogues | NEUROGEN CORPORATION | 2007-08-23 | — | — | US | disclosed |
| US-20070197559-A1 | Aryl substituted purine analogues | NEUROGEN CORPORATION | 2007-08-23 | — | — | US | disclosed |
| EP-1720877-A2 | ARYL SUBSTITUTED PURINE ANALOGUES | Neurogen Corporation (US) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005084401-A2 | ARYL SUBSTITUTED PURINE ANALOGUES | NEUROGEN CORPORATION (US) | 2005-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093757-A1 | THERAPEUTIC AGENTS 414 | GCK, GCKR, GPR119 | GCK 1/4885ALDH1A1 1918/4885MAPT 3944/4885 |
| US-20070197559-A1 | Aryl substituted purine analogues | ADORA2A, GART, P2RX7 | GCK 2306/4885ALDH1A1 569/4885MAPT 4604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.